Path Care®
COMPLETE DIAGNOSTIC SOLUTION
BARCODED | NETWORKED | ACCREDITED

PATHCARE DIAGNOSTICS
PLOT NO. 6-3-1186/1 & 2, GREENLANDS,
BEGUMPET, HYDERABAD, TELANGANA,
ICMR No. : PATHDH (Covid-19)
Ph:- 04061216122

REPORT

Patient Name	: Mr. MANTU HAZARIKA	Reg. No.	: 00252301230081
Age and Sex	: 43 Yrs / Male	PCC Code	: PCL-AS-006
Referring Doctor	: Dr. G M C H	Sample Drawn Date	: 23-Jan-2023 10:14 AM
Referring Customer	: SARMA LAB	Registration Date	: 24-Jan-2023 01:56 PM
Vial ID	: M3002747	Report Date	: 01-Feb-2023 08:03 PM
Sample Type	: *WB-EDTA*	Report Status	: Final Report
Client Address	: *Bhangagarch, Gmch Road,Nanak Nagar,Assam,Guwahati-*		

MOLECULAR BIOLOGY

Test Name	Obtained Value	Units	Bio. Ref. Intervals (Age/Gender specific)	Method
BCR - ABL Gene Rearrangement - Quantitative				
BCR ABL RT-PCR-INTERNATIONAL SCALE				
Observed copies of ABL1	118574.00			
Observed copies of BCR-ABL1	25600.00			
BCR-ABL1/ABL1 Ratio	0.21			
BCR-ABL1/ABL1 % Ratio	21.58			
Conversion factor for IS	0.70			
BCR-ABL1/ABL1 IS % Ratio	15.17			
Log10 BCR-ABL1/ABL1 IS Ratio	1.18			
TRANSCRIPT DETECTED	P210			

Suggested clinical correlation.

Methodology:

Reverse transcription real-time PCR is performed for the BCR-ABL1 fusion transcript with normalization of transcript levels to the ABL1 transcript.

Comments:

Calculations: This report uses the international Scale (IS) to report BCR-ABL transcript levels.

- Minimum amplification of ABL control gene must be 10,000 copies /RT for reporting.
- Percentage ratio between quantities of BCR-ABL and the ABL transcript is generated.
- Results are normalized to the IS scale by multiplying the IS conversion factor.
- IS conversion factor is established with the aid of certified reference material calibrated to the First WHO International Genetic Reference Panel for quantification of BCR-ABL1 translocation by RT- PCR.

Clinical Significance: The percentage reading on the IS is interpreted as follows

- <1% correlates with the level of complete cytogenetic response (CCgR).
- <0.1% equivalent to major molecular response (MMR), which is therapeutic target in CML
- <0.01% (log 4 reduction) OR <0.0032% (log 4.5 reduction) is equivalent to deep molecular response(MR).
- It is recommended that RT PCR must be performed every three months at least until MMR has been achieved, following which it can be repeated.

Correlate Clinically.

*** End Of Report ***

B. Parvathi Devi

DR. B.PARVATHI DEVI
MD MICROBIOLOGY, DCP PATHOLOGY

Note: If the test results are alarming or unexpected,Client is advised to contact the laboratory immediately for possible remedial action.

GAUHATI MEDICAL COLLEGE & HOSPITAL

92

Bhangagarh, Guwahati - 781 032

Registration Fees Rs. 10.00 OUT - PATIENT DEPARTMENT (M. R. D.) Phone No. 8403850322

343/22

22789/23 ADVICE SLIP HEAMATOLOGY 09/02/2023

Hospital No.	22789/23	Deptt. Regd. No.	General
Name	MANTU HAZARIKA	Date	TEOK
Age	43Y0M0D	Caste	TEOK
S. & U. :		P.O./T.O.	Jorhat
Sex	M	District	ASSAM
Name of Father/Husband/Guardian's	BISWAJIT HAZARIKA	State	
Village/Town	TEOK	Occupation	
Local Address			
Victim of			
Religion	Hinduism		

User ID :Bunuma Changmai, Patient Type :General

Dr. Jina Bhattacharyya, Prof & Head
Dr. Smita Das, Associate Professor
Dr. Damodar Das, Assistant Professor
CML Clinic
Thursday

CML

Adv BMA < Cytology & Karyotyping

Rx) Tab Imatinib 400mg
1 tab once daily x Contd.

f/u c̄ CBC after 7 days on Thursday

9/2/23

13/2/23 CML-CP on T. Imatinib
Post BM study - having profuse bleeding through BM site.
Similar h/o malena 1yr back
Patient already given Inj 1gm Tranexa.
Inj botropase, Inj. Vit K.

Adv - Admit & hemat

[signature]

2/3/23.

Δ CML - CP. (Sokal score 0.9 point) intermediate risk. BCR- ABL Quantitative P210 detected

P/A → splenomegaly (+) 10cm BCM.

BCR- ABL1/ABL1 % → 21.58%.

90+

EP 2/3/23

Rx

- BMA → CML CP.

- BMBx - CML. Chronic myeloproliferative disorder.

(1) Tab Imatinib 400 mg P.O OD.

(2) Tab Folic- 5mg P.O OD.

Karyo → 46xy t(9:22) (q34:q11.2) [20]

Sokal score : 0.9 point (intermediate risk)

ELTS score: 1.455 low risk.

(3) Advice - Review with - CBC

- BCR-ABL RQ PCR. (Quantitative) assay after 3 month.

[signature]